EpiPens are auto-injectors containing epinephrine, a drug that can treat or reverse severe allergic reactions, potentially preventing death.
The global epinephrine market was valued at $1.75 billion in 2022 and is projected to reach $4.08 billion by 2030. North America represents over 60% of the market.
EpiPens, however, can be prohibitively expensive in some regions.
In this graphic, Visual Capitalist's Marcus Lu presents estimated EpiPen prices in major global markets, compiled by World Population Review and converted to U.S. dollars as of August 2023.
Why are U.S. Prices so High?
The U.S. stands out as the most expensive market for EpiPens, despite over 1 million Americans having epinephrine prescriptions. After Mylan (now part of Pfizer) acquired the rights to produce EpiPens in the U.S. in 2007, the cost of a two-pack skyrocketed to $600, up from about $60.
*Per unit cost. Commonly sold as a two-pack, meaning total cost is equal to $600
Former Mylan CEO Heather Bresch defended the price hikes to Congress, citing minimal profit margins. Mylan eventually settled with the U.S. government for a nine-figure sum.
Notably, EpiPens are available at a fraction of the cost in other developed countries like Japan, Germany, and Canada.
Making EpiPens More Affordable
Efforts to improve EpiPen affordability are underway in several U.S. states. For instance, the Colorado House approved a $60 price cap on epinephrine, now under review by the state Senate.
Similar measures in Rhode Island, Delaware, Missouri, and Vermont aim to ensure insurance coverage for epinephrine, which is not currently mandatory, although most health plans cover it.
